NCT00704730 · MORE INFO

Limitations, agreements, and source contact

Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer · Source last updated 2021-04-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details: PIs may publish trial results generated at his/ her site with sponsor's prior written consent and only after results of the trial from all participating sites have been released in a multi-center publication coordinated by the sponsor.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

Complete source fields

certain Agreement

other Details: PIs may publish trial results generated at his/ her site with sponsor's prior written consent and only after results of the trial from all participating sites have been released in a multi-center publication coordinated by the sponsor.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice